UPDATE 2-U.S. FDA approves Gilead cancer gene therapy; price set at $373,000
October 18, 2017 at 20:11 PM EDT
Oct 18 (Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.
